GO
Loading...

Enter multiple symbols separated by commas

Boston Scientific Shares Down On Stent Studies; Abbott Moves Higher

Boston Scientific's stock slid on Monday while shares of Abbott Laboratoriesjumped after a study showed Abbott's drug-coated stent was better at treating clogged heart arteries.

"Over the weekend, the competitive landscape in drug-eluting stents was effectively turned on its head," JP Morgan analyst Michael Weinstein said in a note to clients.

Abbott on Saturday presented data that showed its Xience drug-eluting stent was superior to Boston Scientific's market-leading Taxus stent in both its primary goal of reduced reclogging and a secondary goal of fewer adverse cardiac events.

The study results, which will be used to seek U.S. approval for the device, were presented at a major meeting of cardiologists in New Orleans.

"Results from Abbott's U.S. and European DES trials should catapult the company's Xience product into a leadership position in both markets come 2008," Weinstein said.

Weinstein and other analysts raised their earning estimates for Abbott Laboratories following the results.

BMO Capital Markets analyst Joanne Wuensch cut her investment rating on Boston Scientific to "market perform" from "outperform" on Monday, citing the study and renewed worries about the overall health of the market for the wire-mesh devices that emit drugs to prevent vessels from narrowing again.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Street seeks to continue positive momentum

    Futures are pointing to a higher open this morning after U.S. stocks ended a down week on a positive note. Investors are now looking ahead to Friday's April jobs report.

  • CEOs share Warren's wisdom

    John Stumpf, Wells Fargo chairman & CEO; Kenneth Chenault; American Express chairman & CEO; Ginni Rometty, IBM chairman & CEO; and Muhtar Kent, Coca-Cola chairman & CEO, discuss what it's like having Warren Buffett behind you as well as what he looks for in a leader.

  • CEO discuss the 'Buffett factor'

    John Stumpf, Wells Fargo chairman & CEO; Kenneth Chenault; American Express chairman & CEO; Ginni Rometty, IBM chairman & CEO; and Muhtar Kent, Coca-Cola chairman & CEO, discuss their relationships with Warren Buffett and marvel at just how easy it's been to communicate with him.